Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Delaware IP Law Blog
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Intellectual Property Law
: Delaware IP Law BlogJudge Sleet decides issue of first impression: Do the prior art rules of the Patent Act apply to defendants? obviousness-type double patenting defense?
By Karen E. Keller, Andrew A. Lundgren et al.
In Eli Lilly and Co. v. Teva Parenteral Medicines, Inc., C.A. 08-335-GMS (D. Del. Nov. 5, 2010), Judge Sleet recently decided an issue of first impression -- what is the date the court should use to determine what constitutes prior art for purposes of defendants? obviousness-type double patenting defense? Plaintiffs argued that while 35 U.S.C. § 102 governed what references constituted prior art, § 102 did not resolve ?for purposes of an obviousness-type double patenting (?OTDP?) analysis the question . . . in light of the prior art as of what date?? Id. at 2 (emphasis in original). Judge Sleet rejected plaintiffs? distinction between ?the questions of ?what? and ?when?? because adopting plaintiffs? argument would ?require the court to view some portions of [§ 102] as controlling while viewing others as irrelevant in the OTDP context.? Id. If the Federal Circuit intended such a result ? excepting prior art in the OTDP context from the rules found in § 102 ? it would have done so explicitly. Id. at 4-5.
Eli Lilly and Co. v. Teva Parenteral Medicines, Inc., C.A. 08-335-GMS (D. Del. Nov. 5, 2010)
Full post as published by Delaware IP Law Blog on November 09, 2010 (boomark / email).
Discouraging Union Organizers
Strict work place rules
Self Defense
It's legal to defend yourself and your family
VA Sets New Benefit Rules for Agent Orange-Related Ilnesses
Agent Orange-Related Ilnesses VA Sets New Benefit Rules
Philip Morris
Jury Decides Against Big Tobacco
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Type 2 Diabetes
Linked to Arsenic in Water
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
Mr. Brown Instant Coffee
Possible Melamine Contamination Prompts Canadian Agency to Issue Warning

Obviousness-type Double Patenting after Amgen v. F. Hoffmann-La Roche
Boehringer Ingelheim Int'l. v. Barr Laboratories, Inc. (Fed. Cir. 2010)
Terminal Disclaimers and PTO: Proposal for a Test Case
Federal Circuit Affirms Invalidity of Lilly's Gemzar Patent for Obviousness-Type Double Patenting
CAFC: "Graham Analysis" Not Always Required For Double-Patenting
Ending the Doctrine of Non-Statutory Double Patenting







